INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

March 11, 2020

DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

March 10, 2020

-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical activity, CAR T cell expansion and persistence- -Received FDA IND clearance and Orphan Drug...

Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences

February 21, 2020

DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, announced today that it will publish financial results for the fiscal year and...

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

January 13, 2020

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma- -First...

Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38 th...

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
SEC Filings
Investor FAQs
Corporate Deck
2019 Annual Report

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal